10 News & Press Releases found
Ascelia Pharma AB News
-
New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population
Ascelia Pharma today announced and welcomed the results of independent market research showing that 84% of healthcare professionals will likely use Orviglance for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced ...
-
Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the last patient visit has been completed in the clinical study to evaluate the effect of liver impairment on the safety, pharmacokinetics and pharmacodynamics of the company’s lead ...
-
Ascelia Pharma suspends clinical activities in Russia
Ascelia Pharma AB (publ) (ticker: ACE) today announced that due to the Russian invasion of Ukraine, all clinical activities in Russia in the ongoing Phase 3 study SPARKLE are being suspended. As a consequence, the expected recruitment completion ...
-
Results from Orviglance comparison study to gadolinium accepted for oral presentation at the ESGAR confere
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the study where Orviglance was compared against a gadolinium-based contrast agent has been accepted as an oral scientific presentation at the ESGAR conference to be held in May 31 – ...
-
Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for the upcoming global Phase 2 clinical study in gastric cancer ...
-
Results from Orviglance comparison study to gadolinium presented at RSNA 2021
Ascelia Pharma AB (publ) (ticker: ACE) today presented results at the world’s largest radiology conference, RSNA, in Chicago, Illinois from the study in which the investigational contrast agent Orviglance® was compared against a ...
-
Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB
In accordance with the instructions for the Nomination Committee in Ascelia Pharma, the Nomination Committee shall consist of four members representing the three largest shareholders together with the chairman of the board of directors. The ...
-
Ascelia Pharma’s Food Effect Study with Orviglance successfully completed
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the last patient visit has been completed in the study to evaluate the effect of food intake on the absorption of Orviglance (Mangoral). This Food Effect Study is part of the ongoing ...
-
Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF
Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has signed a clinical collaboration agreement with Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. The collaboration concerns an upcoming global Phase 2 clinical ...
-
Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy
Ascelia Pharma AB (publ) (ticker: ACE) today announced the clinical development plan for Oncoral. With Oncoral, Ascelia Pharma has the opportunity to develop a novel oral chemotherapy with the potential to offer both efficacy and safety benefits to ...